AstraZeneca (LSE:AZN) Filing Acceptance In Europe And Japan Puts Lung Cancer Combo Forward

What happened: AstraZeneca (LSE:AZN) secured acceptance of regulatory filings in Europe and Japan for the TAGRISSO plus ORPATHYS regimen in MET driven, EGFR mutated non small cell lung cancer, backed by phase III data. Key numbers: £213.4b pharmaceuticals group; 2026 guidance assumes mid to high single digit top line growth and low double digit core EPS Why it matters: The filings extend TAGRISSO into later lines of treatment, supporting a combination approach where one backbone therapy carries multiple targeted add ons. Regulatory outcomes and label details are the markers to watch. Market: +1.9% today ($187.45), +3.4% YTD, 0.3x vol — as of 15:18 UTC

AstraZeneca (LSE:AZN) secured acceptance of regulatory filings in Europe and Japan for the TAGRISSO plus ORPATHYS regimen in MET driven, EGFR mutated non small cell lung cancer, backed by phase III data.

The filings extend TAGRISSO into later lines of treatment, supporting a combination approach where one backbone therapy carries multiple targeted add ons. Regulatory outcomes and label details are the markers to watch. Market: +1.9% today ($187.45), +3.4% YTD, 0.3x vol — as of 15:18 UTC